← Back to Search

Non-nucleoside Reverse Transcriptase Inhibitor

DPC 083 + NRTIs for HIV Infection

Phase 2

Waitlist Available

Led By Charles Walworth

Research Sponsored by Dupont Applied Biosciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

At least 18 years old

Weigh at least 50 kg

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will test the safety of DPC 083, an NNRTI, in combination with 2 NRTIs in HIV-infected patients who have failed NNRTI treatment.

Who is the study for?

This trial is for adults over 18 with HIV who are failing NNRTI treatment. They must weigh at least 50 kg, have a viral load of ≥1,000 copies/ml, and show virologic failure on current NNRTIs. Participants need documented HIV genotype results and agree to use effective barrier contraception. Excluded are those with certain medical conditions or treatments that could affect the study.Check my eligibility

What is being tested?

The trial tests DPC 083's safety/effectiveness combined with two NRTIs in patients whose HIV isn't responding to current NNRTI therapy. It aims to see if DPC 083 can lower viral loads where other NNRTIs failed due to drug resistance.See study design

What are the potential side effects?

Potential side effects may include typical antiretroviral reactions such as nausea, headaches, fatigue, and possible allergic reactions. As this is a test for safety and tolerability, close monitoring will identify any additional specific side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I weigh at least 50 kg.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Dupont Applied BiosciencesLead Sponsor

11 Previous Clinical Trials

2,854 Total Patients Enrolled

Charles WalworthPrincipal Investigator

Daniel SeekinsPrincipal Investigator

Media Library

DPC 083 (Non-nucleoside Reverse Transcriptase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00007449 — Phase 2

Human Immunodeficiency Virus Infection Research Study Groups:

Human Immunodeficiency Virus Infection Clinical Trial 2023: DPC 083 Highlights & Side Effects. Trial Name: NCT00007449 — Phase 2

DPC 083 (Non-nucleoside Reverse Transcriptase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00007449 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the risks associated with this treatment option?

"There is limited data surrounding the safety of this treatment, as it is still in Phase 2 trials. This means that while there have been no reports of efficacy, there have also been no serious safety concerns raised."

Answered by AI

Does this research take into account patients that are over 35 years old?

"This trial is only open to patients that are 18 years old or younger. There are a total of 110 studies for patients under the age of eighteen and 367 for patients over the age of sixty-five."

Answered by AI

Is this study taking place at a large number of hospitals across America?

"Right now, there are 5 sites where this trial is enrolling patients. The locations are in Los Angeles and Bradenton as well as Tampa with other centres located nearby. If you choose to participate it would be convenient to select the location nearest you to reduce travel time."

Answered by AI

How can I become involved in this research project?

"This trial is looking for 30 individuals that are infected with HIV and meet the following criteria: Be between 18-0 years old, weigh a minimum of 50 kg, use an effective barrier method of birth control during the study (oral or skin-based contraceptives can not be the only form of birth control), have a screening HIV genotype done while receiving NNRTI treatment or within 2 weeks after stopping treatment, have documented evidence of virologic failure, and have a viral load of at least 1,000 copies/ml within 45 days prior to Day 1 of the study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety and Effectiveness of the Drug DPC 083 in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Patients Who Are Failing Treatment With Nonnucleoside Reverse Transcriptase Inhibitors

2024. "Safety and Effectiveness of the Drug DPC 083 in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Patients Who Are Failing Treatment With Nonnucleoside Reverse Transcriptase Inhibitors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00007449.

All > Hiv Infection > Cte